Floatz logo

nm21-1480

Peritoneal Carcinoma

Numab Therapeutics AGPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Peritoneal Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
CanariaBio Inc.
Phase 3BB
STAPULDENCEL
SOTIO a.s.
Phase 3B
Eloxatin
University of Utah
Phase 2B
Interferon Gamma-1B
InterMune
Phase 3B
Arimidex
Massachusetts General Hospital
Phase 2B

View all 18 →

Same molecule, other indications

nm21-1480 is also rated in:

squamous cell carcinomaDormant
CC
Indicative ·
45 / 100
View asset →
ovarian carcinomaDormant
CC
Indicative ·
45 / 100
View asset →
fallopian tube cancerDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →